| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.05(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,189 |
| 52
Week Range: |
$120.4 - $292.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 27 |
| Insider 3/6 Months : 27.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
| Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
| Total People Sold |
5 |
7 |
7 |
8 |
| Total Sell Transactions |
13 |
21 |
21 |
26 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Craves Fred B |
Director |
– • • |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
296,067 |
296,067 |
|
- |
|
| Friedman Paul A |
Chief Executive Officer |
• • – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
729,066 |
729,066 |
|
- |
|
| Friedman Paul A |
Chief Executive Officer |
• • – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
143,703 |
143,703 |
|
- |
|
| Taub Rebecca |
Chief Medical Officer, EVP R&D |
• • • |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
432,872 |
432,872 |
|
- |
|
| Taub Rebecca |
Chief Medical Officer, EVP R&D |
• • • |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
729,066 |
729,066 |
|
- |
|
| Schneebaum Marc R |
Chief Financial Officer |
• – – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
22,969 |
42,277 |
|
- |
|
| Schor Chen |
Former President and CEO |
• • – |
2016-07-22 |
4 |
D |
$9.48 |
$135,090 |
D/D |
(14,250) |
37,178 |
|
- |
|
| Schor Chen |
Former President and CEO |
• • – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
42,857 |
51,428 |
|
- |
|
| Schneebaum Marc R |
SVP and CFO |
• – – |
2016-07-22 |
4 |
D |
$9.48 |
$81,035 |
D/D |
(8,548) |
19,308 |
|
- |
|
| Schneebaum Marc R |
SVP and CFO |
• – – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
25,714 |
27,856 |
|
- |
|
| Rieder Wendy E |
Former SVP, Gen. Counsel |
• – – |
2016-07-22 |
4 |
D |
$9.48 |
$81,054 |
D/D |
(8,550) |
17,730 |
|
- |
|
| Rieder Wendy E |
Former SVP, Gen. Counsel |
• – – |
2016-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
25,714 |
26,280 |
|
- |
|
| Morenstein Scott D |
Director |
– • – |
2016-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,857 |
17,857 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2015-12-14 |
4 |
S |
$0.32 |
$96,690 |
I/I |
(300,000) |
1,539,169 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2015-12-11 |
4 |
S |
$0.37 |
$111,030 |
I/I |
(300,000) |
1,839,169 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2015-12-09 |
4 |
S |
$0.38 |
$55,235 |
I/I |
(145,892) |
2,139,169 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2015-12-08 |
4 |
S |
$0.38 |
$114,060 |
I/I |
(300,000) |
2,285,061 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-12-08 |
4 |
S |
$0.37 |
$506,766 |
I/I |
(1,369,639) |
340,970 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2015-12-07 |
4 |
S |
$0.39 |
$115,830 |
I/I |
(300,000) |
2,585,061 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-12-07 |
4 |
S |
$0.41 |
$41 |
I/I |
(100) |
836,985 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-12-04 |
4 |
S |
$0.41 |
$63,348 |
I/I |
(153,607) |
837,021 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-12-03 |
4 |
S |
$0.41 |
$108,621 |
I/I |
(262,434) |
892,650 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-12-02 |
4 |
S |
$0.43 |
$293,744 |
I/I |
(687,603) |
987,690 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-12-01 |
4 |
S |
$0.43 |
$206,804 |
I/I |
(480,716) |
1,236,705 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2015-11-30 |
4 |
S |
$0.43 |
$277,659 |
I/I |
(640,505) |
1,410,796 |
|
- |
|
413 Records found
|
|
Page 6 of 17 |
|
|
1.67 (0.81%) 
